FPH 2025 Notice of Annual Meeting and Voting Form

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

2025 Notice of Annual Shareholders’ Meeting and Voting Form

Auckland, New Zealand, 10 July 2025 – Fisher & Paykel Healthcare Corporation Limited (NZX:FPH,
ASX:FPH) has provided a copy of the Notice of Meeting for its 2025 Annual Shareholders’ Meeting,
which will be held in person at 15 Maurice Paykel Place, East Tāmaki, Auckland, New Zealand on
Thursday, 21 August 2025 at 2.00pm (NZST) and online at www.virtualmeeting.co.nz/FPH25.

The attached Notice of Meeting and Voting Form will be mailed to shareholders who have not
provided the company’s share registrar with an email address. An electronic copy of these
documents is also available on the company’s website at www.fphcare.com/asm.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com.

Contacts:

Media Investors
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911
Dan Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 22 511 4050

Authorised by Raelene Leonard, General Counsel and Company Secretary.

---

Fisher & Paykel Healthcare Corporation Limited
NOTICE OF ANNUAL
SHAREHOLDERS’
MEETING 2025

The Annual Shareholders’ Meeting of
Fisher & Paykel Healthcare Corporation
Limited (NZBN 9429040719887 and
ABN 69 098 026 281) (the company) will be
held online at www.virtualmeeting.co.nz/FPH25
and in person at 15 Maurice Paykel Place,
East Tāmaki, Auckland, New Zealand on
Thursday, 21 August 2025 commencing
at 2.00pm (NZST).

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 20251
TE AHUNGA
CAR PARK
PAYKEL
BUILDING
DANIELL
BUILDING
O’HARE
BUILDING
STEWART
BUILDING
IMPORTANT DATES
Record date for
voting entitlements
for the Annual
Shareholders’ Meeting
5.00pm
Tuesday, 19 August 2025
(NZST)
Latest time for
receipt of postal votes
and proxies
2.00pm
Tuesday, 19 August 2025
(NZST)
Annual Shareholders’
Meeting
2.00pm
Thursday, 21 August 2025
(NZST)
HOW TO GET TO
THE DANIELL BUILDING
AT 15 MAURICE PAYKEL
PLACE, EAST TĀMAKI,
AUCKLAND
At the roundabout at the end
of Maurice Paykel Place, take
the second exit and follow the
signs to the Daniell Building.
Visitor parking is clearly
marked and is available
outside the Daniell Building.
HIGHBROOK DRIVE
MAURICE
PAYKEL PLACE

Fisher & Paykel Healthcare Corporation Limited
2
BUSINESS
A. CHAIR’S ADDRESS
B. MANAGING DIRECTOR AND
CHIEF EXECUTIVE OFFICER’S REVIEW
C. FINANCIAL STATEMENTS
To receive and consider the financial statements and
the auditor’s report for the year ended 31 March 2025
as contained in the company’s 2025 annual report.
D. RESOLUTIONS
To consider and, if thought appropriate, pass the
following ordinary resolutions.
Re-Election of Directors
(1) That Neville Mitchell be re-elected
as a director of the company.
(2) That Lewis Gradon be re-elected
as a director of the company.
(3) That Lisa McIntyre be re-elected
as a director of the company.
(4) That Cather Simpson be re-elected
as a director of the company.
(See Explanatory Note 1)
Election of Director
(5) That Mark Cross be elected as a
director of the company.
(See Explanatory Note 2)

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 20253
Auditor’s Remuneration
(6) That the Directors be authorised to fix the fees
and expenses of PwC as the company’s auditor.
(See Explanatory Note 3)
Long Term Variable Remuneration issued to the
Managing Director and Chief Executive Officer
(7) That the grant of discretionary long term
variable remuneration instruments to
Lewis Gradon, Managing Director and
Chief Executive Officer, as described in
explanatory note 4 be approved.
(See Explanatory Note 4)
SHAREHOLDER QUESTIONS
Consideration of any shareholder questions raised
during the meeting.
By Order of the Board of Directors
NEVILLE MITCHELL, CHAIR
10 JULY 2025

Fisher & Paykel Healthcare Corporation Limited
4
PROCEDURAL NOTES
Persons entitled to vote
The persons who will be entitled to vote on the
resolutions at the Annual Shareholders’ Meeting
are those persons who will be the shareholders
of the company at 5.00pm on Tuesday,
19 August 2025 (NZST).
Casting a vote
The voting form enclosed with this notice allows
you, or your proxy, to vote either for or against,
or abstain from, each of the resolutions. Votes may
be cast in any one of the following ways:
Meeting attendance
Attending in person:
Shareholders present at the Annual Shareholders’
Meeting in person may cast their votes at the
meeting. A paper voting card will be issued upon
registration at the meeting.
Attending online:
To attend the meeting online please go to
www.virtualmeeting.co.nz/FPH25. Shareholders
attending online will be able to vote and ask
questions during the Annual Meeting. More
information regarding virtual attendance at the
Annual Meeting (including how to vote and ask
questions virtually during the Meeting) is
available in the Virtual Meeting Guide available at
https://mail.cm.mpms.mufg.com/MUFG/MUFG_
VirtualMeetingGuide.pdf.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 20255
Online and postal voting prior to the meeting
Shareholders may directly cast a vote prior to the
meeting online at vote.cm.mpms.mufg.com/FPH
or by post by completing and lodging the enclosed
voting form with the share registrar, MUFG Corporate
Markets (previously Link Market Services Limited),
at PO Box 91976, Auckland 1142, New Zealand, in
accordance with the instructions set out on the form.
In either case, the vote must reach MUFG Corporate
Markets not later than 48 business hours before the
time of the holding of the meeting (i.e. before 2.00pm
on Tuesday, 19 August 2025 (NZST)). The Board has
authorised MUFG Corporate Markets to receive and
count postal votes.
Proxy
Shareholders may appoint a proxy to attend the
Annual Shareholders’ Meeting and vote in their place.
A body corporate which is a shareholder may appoint
a representative to attend on its behalf in the same
manner as that in which it could appoint a proxy.
A proxy need not be a shareholder of the company.
A shareholder who wishes to do so may appoint the
Chair of the Meeting to act as proxy.
A proxy will vote as directed in the proxy form or, if
voting is left to the proxy’s discretion, the proxy will
decide how to vote on the resolutions (subject to the
comments under “Voting Restrictions” below). If the
Chair is appointed as proxy and the voting is left to
his discretion, the Chair intends to vote in favour of
each of Resolutions (1) to (7).
To appoint a proxy, go online to vote.cm.mpms.mufg.
com/FPH or complete and lodge the enclosed voting
form with the share registrar, MUFG Corporate
Markets, in accordance with the instructions set out
on the form. In either case, the proxy must be received
not later than 48 business hours before the time of the
holding of the meeting (i.e. before 2.00pm on Tuesday,
19 August 2025 (NZST)).

Fisher & Paykel Healthcare Corporation Limited
6
Voting Restrictions
The company will disregard any votes cast in favour
of Resolution (7) by Lewis Gradon and any of his
associated persons (in each case the term “associated
persons” is as defined in the NZX Listing Rules).
The company need not disregard a vote cast in
favour of Resolution (7) if it is cast by any of the above
people as proxy for a person who is entitled to vote,
in accordance with an express direction on the
proxy form.
Resolutions
All the resolutions contained in this Notice of Meeting
must be passed by an ordinary resolution of
shareholders, i.e. by a simple majority of the votes of
those shareholders entitled to vote and voting on the
resolution in person or by proxy.
NZX
This Notice of Meeting has been reviewed by NZX
Regulation Limited (NZ RegCo) in accordance with
NZX Listing Rule 7.1 and NZ RegCo has confirmed it
does not object to this Notice. NZ RegCo does not
take any responsibility for any statement in this Notice.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 20257
EXPLANATORY NOTE 1 –
RE-ELECTION OF DIRECTORS
Under NZX Listing Rule 2.7, a Director must not
hold office (without re-election) past the third annual
meeting following the Director’s appointment or three
years, whichever is the longer.
Neville Mitchell, Lewis Gradon, Lisa McIntyre and
Cather Simpson are the Directors retiring in 2025.
Being eligible, Neville Mitchell, Lewis Gradon, Lisa
McIntyre and Cather Simpson offer themselves for
re-election.
All four Directors standing for re-election do so
with the support of the Board, having considered
the tenure, contribution to the Board, attendance,
experience, other commitments and positions, and
performance generally for each of Neville Mitchell,
Lewis Gradon, Lisa McIntyre and Cather Simpson.
EXPLANATORY NOTES
Neville Mitchell
Neville was Chief Financial Officer and Company
Secretary of Cochlear Limited between 1995 and 2017.
He is a director of Sonic Healthcare and Sigma
Healthcare, and a former director of The Board of Tax,
South Eastern Sydney Local Health District, Osprey
Medical and Sirtex Medical. Previously, he served on
the New South Wales Medical Devices Fund, was
Chairman of the Group of 100, and Chairman, Standing
Committee (Accounting and Auditing) for the
Australian Securities and Investments Commission.
Neville Mitchell is considered by the Board to be an
independent Director.

Fisher & Paykel Healthcare Corporation Limited
8
Lewis Gradon
Lewis became Managing Director and Chief Executive
Officer in April 2016. Prior to that, he spent 15 years as
Senior Vice President – Products & Technology, and
six years as General Manager – Research & Development.
During his 42-year tenure with Fisher & Paykel Healthcare,
he has held various engineering positions overseeing
the development of our range of products as well as the
development of our manufacturing, quality, intellectual
property, supply chain and clinical research functions.
Lewis Gradon is considered by the Board to be a
non-independent Director.
Lisa McIntyre
Lisa is a director of The University of Sydney, Studiosity,
Nanosonics and Baymatob. She has previously been a
director of a range of health entities, including those in
healthcare insurance, clinical service delivery and medical
research and innovation. Lisa spent 20 years as a senior
strategy partner with LEK Consulting providing advice
to companies in North America, Asia and Australia.
Lisa McIntyre is considered by the Board to be an
independent Director.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 20259
Cather Simpson
Cather is a professor of physics and chemical
sciences at the University of Auckland, CEO of Orbis
Diagnostics and a partner at Pacific Channel, with
expertise in lasers and photonics. She is Vice President
of the International Society for Optics & Photonics
(SPIE) and a member of the Academy Executive
Committee of the Royal Society Te Apārangi. Cather
is a co-founder of three hard-tech start-ups, including
Engender Technologies, where she served as Chief
Science Officer from 2011 to 2021. She founded and
directed the Photon Factory at the University of
Auckland in 2010.
Cather Simpson is considered by the Board to be
an independent Director.

Fisher & Paykel Healthcare Corporation Limited
10
EXPLANATORY NOTE 2 – ELECTION OF DIRECTOR
Under NZX Listing Rule 2.7, a Director appointed
by the Board must not hold office (without election)
past the next annual meeting following the Director’s
appointment.
Mark Cross was appointed by the Board as a Director
of the company with effect from 1 October 2024.
Accordingly, Mark Cross offers himself up for election
at the Annual Shareholders’ Meeting.
Mark Cross stands for election with the support of
the Board.
Mark Cross
Mark chairs the board of Chorus and is a director
of Xero. He is a board member of Accident
Compensation Corporation (ACC) and chair of the
ACC Investment Committee. He is a former chair of
Milford Asset Management and a former director
of Z Energy, Genesis Energy and Argosy Property.
Mark previously held executive investment banking
positions with Deutsche Bank and Lloyds Corporate
Finance/Southpac Corporation, where he was an
advisor to companies across a range of sectors.
He is a member of Chartered Accountants Australia
and New Zealand, a member of the Australian Institute
of Company Directors and a Chartered Fellow of the
Institute of Directors.
Mark Cross is considered by the Board to be an
independent Director.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 202511
EXPLANATORY NOTE 3 – AUDITOR’S
REMUNERATION
Under section 207T of the Companies Act 1993,
PwC is automatically reappointed as the auditor of the
company, and this resolution authorises the Board to
fix the fees and expenses of the auditor in accordance
with section 207S of the Companies Act 1993.
EXPLANATORY NOTE 4 – LONG TERM VARIABLE
REMUNERATION ISSUED TO THE MANAGING
DIRECTOR AND CHIEF EXECUTIVE OFFICER
Introduction
Resolution (7) seeks approval for the grant of
equity-based discretionary long term variable
remuneration instruments (DLTVR Instruments) to
Lewis Gradon, the company’s Chief Executive Officer
and Managing Director.
This year, the Board has conducted a review of the
DLTVR Instruments issued to executives, senior
managers and selected high-performing employees
of the company.
As a result of that review, the Board has approved
minor modifications to the company’s discretionary
long term variable remuneration arrangements
(DLTVR Plans) under which DLTVR Instruments will be
issued. A summary of the updated DLTVR Plans is set
out below. The Board is of the view that the updated
plans create better alignment in outcomes for
employees and shareholders taking account of the
company’s performance compared to the markets and
industry in which the company operates.

Fisher & Paykel Healthcare Corporation Limited
12
Shareholder approval for the issue of DLTVR
Instruments to Mr Gradon is not required under the
company’s constitution or the NZX Listing Rules,
because the number of securities issued to all
employees will not exceed the three percent issuance
capacity permitted by Rule 4.6 of the NZX Listing
Rules, and DLTVR Instruments will be granted to
Mr Gradon under allocation criteria applying to
employees generally. However, consistent with prior
practice, the Board has decided to seek approval of
the grant to Mr Gradon, because the Board sees it as
good corporate governance to obtain shareholder
approval for the issue of securities to directors. If
shareholders do not approve the issue, the Board will
investigate alternative long term variable remuneration
arrangements for Mr Gradon. If shareholders approve
the issue, DLTVR Instruments will be granted to
Mr Gradon within one month after the Annual
Shareholders’ Meeting.
Performance share rights (PSRs) and share options
(Options) are awarded to Mr Gradon and other
members of the company’s executive management
team.
A summary of the terms of PSRs and Options is set
out below and is available on the company’s website
at https://www.fphcare.com/nz/corporate/
sustainability/governance/long-term-variable-
remuneration-plans/.
A holder of PSRs or Options is called a “participant”
below.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 202513
Purpose and nature
The Board believes that the issue of PSRs and
Options to executive management provides
appropriate alignment of the interests of those
employees with the interests of shareholders over
the long term. PSRs and Options also assist the
company to attract, motivate and retain executives
in an environment where such employees are in high
demand, both within New Zealand and internationally.
Each PSR entitles a participant, subject to the
satisfaction of the vesting conditions described
below, to receive one ordinary share in the company
for no payment. Each Option entitles a participant,
subject to those conditions, to receive one ordinary
share on payment of an amount per share equal to
the price of shares on the NZX as at the date the
Option is granted to the participant (calculated on the
basis of the volume weighted average price over the
five trading days before that date).
No amount is payable by a participant for the grant
of PSRs or Options.
Value of instruments
Mr Gradon will be offered PSRs and Options having
a total value of $1,272,726. Prior to the grant date,
Mr Gradon will be entitled to choose the proportion
of PSRs and Options to make up the total value to
be issued to him. The value of each PSR and Option
will be determined by an independent valuation
undertaken by KPMG following the Annual
Shareholders’ Meeting. The number of PSRs to be
granted to Mr Gradon will equal the proportion of
$1,272,726 that Mr Gradon has chosen to receive as
PSRs (in dollar terms) divided by the value of each
PSR as determined by KPMG, and the number of
Options to be granted to Mr Gradon will equal the
proportion of $1,272,726 that Mr Gradon has chosen
to receive as Options (in dollar terms) divided by
the value of each Option as determined by KPMG.

Fisher & Paykel Healthcare Corporation Limited
14
Vesting conditions
A holder of PSRs or Options receives no benefit from
them unless they vest (subject to the first paragraph
under “Discretions for Board” below). PSRs and
Options which do not vest lapse and are no longer
available. The provisions as to vesting are as follows:
• On the third anniversary of the grant of PSRs and
Options, the PSRs and Options held by each holder
are each notionally divided into two equal parts,
called the “DJSMDQT Tranche” and the “ASX 200
Tranche”.
• The company determines the total shareholder
return (TSR) on the company’s ordinary shares
over the three-year period from the grant of PSRs
and Options to the third anniversary. That is made
up of the change in share price on the NZX over
that period and the impact of dividends over
that period.
• The TSR is then compared to the change over the
same period in:
–DJSMDQT Tranche: the Dow Jones US Select
Medical Equipment Total Return Index; and
–ASX 200 Tranche: the S&P/ASX 200 Gross
Total Return Index.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 202515
• The number (if any) of PSRs and Options that vest
is determined in accordance with the table below:
Performance of TSR
against relevant index
Percentage of PSRs
and Options that vest
TSR less than the return
on relevant index
Nil
TSR exceeds the return
on relevant index by
10 percentage points
or more
100%
TSR equal to or exceeds
the return on relevant
index by less than
10 percentage points
A number calculated in
accordance with a formula
which produces a percentage,
calculated on a straight-line
basis, between 50% if the TSR
is equal to the return on the
relevant index, and 100% if the
TSR exceeds the return on the
relevant index by 10 percentage
points or more
• For the purposes of the calculations above:
–share prices and index figures on a particular
date are determined by reference to the average
prices or index figures over the five trading days
before that date;
–the returns on the DJSMDQT Index and ASX 200
Index are converted to NZ dollars using spot
exchange rates.
Ceasing employment
Unless otherwise determined by the Board, PSRs and
Options lapse if a participant ceases to be employed
by the group. If a participant ceases to be employed
by reason of death, serious illness, accident,
permanent disablement, or redundancy, the PSRs
and Options will remain in force, subject to vesting
in accordance with the provisions described above.

Fisher & Paykel Healthcare Corporation Limited
16
Clawback
If a participant:
• commits an act of serious misconduct as an
employee; or
• is knowingly involved in a material overstatement
of financial performance or position in the group’s
accounts,
the Board may cancel the PSRs or Options held by
that participant and require repayment of any gain
made by that participant from PSRs or Options as
a result of such conduct.
Discretions for Board
The Board has various discretions under the DLTVR
Plans governing the PSRs and Options, including:
• a discretion to allow PSRs or Options to vest if the
Board decides that particular circumstances justify
the exercise of that discretion;
• a discretion to amend the terms of PSRs or Options
to take account of capital reconstructions or the
like, so as to ensure that so far as reasonably
possible no benefit is conferred on participants that
is not conferred on shareholders, and vice versa;
• a discretion, in the event of a takeover of the
company or the like, to take various steps to enable
participants to participate in, or benefit from, that
transaction; and
• a discretion to amend the terms of the DLTVR
Plans.

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING 202517

---

Lodge your proxy:
Online: vote.cm.mpms.mufg.com/FPH
Scan and email: meetings.nz@cm.mpms.mufg.com
(use “FPH Proxy Form” as the subject for easy
identification)
Mail: Use the enclosed reply paid envelope or
address to:
MUFG Corporate Markets
PO Box 91976, Auckland 1142, New Zealand
By hand:
MUFG Corporate Markets
Level 30, PwC Tower
15 Customs Street West, Auckland, New Zealand
General enquiries:
+64 9 375 5998 or email:
enquiries.nz@cm.mpms.mufg.com
SCAN THIS QR CODE WITH YOUR
SMARTPHONE AND VOTE ONLINE
Fisher & Paykel Healthcare Corporation Limited Annual Meeting Voting Form
The Annual Shareholders’ Meeting of Fisher & Paykel Healthcare Corporation Limited (NZBN 9429040719887 and ABN
69 098 026 281) (the company) will be held online at www.virtualmeeting.co.nz/FPH25 and in person at the company’s
East Tāmaki campus in the Daniell Building, 15 Maurice Paykel Place, East Tāmaki, Auckland, New Zealand on Thursday,
21 August 2025 commencing at 2.00pm (NZST). To attend online via the above link, you will require your Holder Number
for verification purposes.
8 A proxy can be any person of your choice and does not have
to be a shareholder of Fisher & Paykel Healthcare. If you wish,
you can appoint the Chair of the Meeting as your proxy. The
Chair will vote in accordance with your instructions, or, failing
your instruction, in accordance with the terms set out in
paragraph 9 of this Voting Form.
9 If you tick the box “Discretion” on any resolution, you are
directing your proxy or representative to decide how to vote on
that resolution on your behalf. If you tick the “Abstain” box on
any resolution, you are directing your proxy or representative not
to vote on that resolution. If you return this Voting Form without
a direction as to how to vote on any resolution, or if you tick
more than one box in relation to any resolution, the vote on that
resolution will be treated as “Discretion” and your proxy will
exercise his/her discretion as to whether to vote and, if so, how.
The Chair intends to vote discretionary proxies in favour of
Resolutions 1, 2, 3, 4, 5, 6, and 7.
10 This Voting Form must be signed by you or your attorney, duly
authorised in writing. In the case of a joint shareholding, this
form must be signed by each of the joint shareholders (or their
duly authorised attorney). In the case of a corporate shareholder,
this Voting Form must be signed by a director or a duly
authorised officer acting under the express or implied authority
of the corporate shareholder, or an attorney duly authorised by
the corporate shareholder.
11 If this Voting Form is signed under a power of attorney, a
certificate of non-revocation must be completed and a copy
of the power of attorney certified by a Solicitor, Justice of the
Peace or Notary Public provided to MUFG Corporate Markets,
unless it has already been noted by the company or MUFG
Corporate Markets.
General
12 The company will disregard any votes cast in favour of
Resolution 7 by Lewis Gradon and any of his associated persons
(in each case as that term is defined in the NZX Listing Rules).
13 The company need not disregard a vote cast in favour of
Resolution 7 by a person referred to in paragraph 12 if that
vote is cast by that person as proxy for a person who is entitled
to vote, in accordance with an express direction on the
Voting Form.
NOTES
Attending the Meeting
1 If you propose to ATTEND the Annual Shareholders’ Meeting in
person, please bring this Voting Form to the meeting to assist
with your registration. All shareholders must register with MUFG
Corporate Markets prior to entering the meeting room. A paper
voting card will be issued upon registration at the meeting.
2 Shareholders attending and participating in the Annual Meeting
virtually via www.virtualmeeting.co.nz/FPH25 will be able to vote
and ask questions during the Annual Meeting. More information
regarding virtual attendance at the Annual Meeting (including how
to vote and ask questions virtually during the Meeting) is available
in the Virtual Meeting Guide available at https://mail.cm.mpms.
mufg.com/MUFG/MUFG_VirtualMeetingGuide.pdf.
Postal Vote
3 If you are entitled to attend and vote at the Annual Shareholders’
Meeting, you are entitled to vote by postal vote. The Company
Secretary has been authorised by the Board to receive and count
postal votes at the Annual Meeting.
4 You can cast your postal vote by one of the methods listed above
in the box headed “Lodge your proxy”. If you return your postal
vote without indicating how you wish to vote, or your indication
on how to vote is unclear on any resolution, you will be deemed
to have abstained from voting on that resolution.
5 If you complete the postal vote section and also appoint a proxy,
your postal vote will be cast and your proxy appointment will not
be counted.
6 If this Voting Form is returned duly signed by a shareholder with
voting instructions completed, but without indicating that it is a
postal vote, and a proxy has not been appointed, it will be deemed
to be a postal vote.
Proxy Appointment
7 If you are a shareholder entitled to attend and vote at the Annual
Shareholders’ Meeting, you are entitled to appoint a proxy or, in
the case of a corporate shareholder, a representative to attend and
vote instead of you. A proxy may be appointed by completing a
Voting Form online, or the Voting Form may be completed and
mailed, delivered, or scanned and emailed in accordance with the
instructions above in the box headed “Lodge your proxy”.
For your postal vote or proxy to be effective, it must be lodged with MUFG Corporate Markets
by no later than 2.00pm, Tuesday, 19 August 2025 (NZST).
Go online to vote.cm.mpms.mufg.com/FPH to cast your vote or appoint your proxy, or turn over to complete the form.

Section 2:
Voting instructions
This form is to be used to vote as follows on the following resolutions: Tick (
ü
) in box to record your vote
BusinessForAgainstAbstainDiscretion
1.To re-elect Neville Mitchell as a director

2.To re-elect Lewis Gradon as a director

3.To re-elect Lisa McIntyre as a director

4.To re-elect Cather Simpson as a director

5.To elect Mark Cross as a director

6.To authorise the Directors to fix the fees and expenses of the auditor

7.To approve the grant of discretionary long term variable remuneration
instruments to Lewis Gradon

The resolutions above are stated in brief. Please refer to the Notice of Annual Shareholders’ Meeting 2025 for the full text of the
resolutions and the explanatory notes.
Section 1:
Choose to vote by postal vote or appoint a proxy to vote on your behalf
Postal Voting
I wish to vote by postal vote (please tick the box). My voting intention is indicated in the resolution section below.
Appoint a proxy to vote on your behalf
I/We being a shareholder(s) of
Fisher & Paykel Healthcare Corporation Limited hereby appoint: at:
(full name of proxy) (email)
Or failing that person: at:
(full name of proxy) (email)
as my/our proxy to vote for me/us on my/our behalf as directed below, and on any other matters put to the Annual Shareholders’
Meeting of Fisher & Paykel Healthcare Corporation Limited to be held at 2:00pm on Thursday, 21 August 2025 (NZST), or at any
adjournment of that meeting. Unless otherwise instructed as below, my/our proxy may vote as he/she thinks fit.
If you wish, you may appoint the Chair of the Meeting as your proxy by entering “Chair of the Meeting” in the box above.
Sign:
Signature of shareholder(s). This section must be completed.
Contact details
Signed this 2025
(Daytime phone number) (Date)
Signature(s)
(All shareholders must sign your email)

Please tick here if you would like to receive communications electronically – please provide your email address or
email enquiries.nz@cm.mpms.mufg.com to receive shareholder communications electronically.